Insider Transactions in Q4 2020 at Arrowhead Pharmaceuticals, Inc. (ARWR)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2020
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
599
-0.02%
|
-
|
|
Dec 28
2020
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
1,126
-0.04%
|
-
|
|
Dec 22
2020
|
Douglas B Given Director |
SELL
Bona fide gift
|
Direct |
35
-0.03%
|
-
|
|
Dec 21
2020
|
Douglas B Given Director |
SELL
Bona fide gift
|
Direct |
235
-0.1%
|
-
|
|
Dec 18
2020
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,510
+0.79%
|
$202,550
$5.45 P/Share
|
|
Dec 17
2020
|
Douglas B Given Director |
SELL
Bona fide gift
|
Direct |
600
-0.09%
|
-
|
|
Dec 17
2020
|
Douglas B Given Director |
SELL
Open market or private sale
|
Indirect |
500
-3.23%
|
$39,500
$79.59 P/Share
|
|
Dec 17
2020
|
Douglas B Given Director |
SELL
Open market or private sale
|
Direct |
9,075
-7.33%
|
$716,925
$79.3 P/Share
|
|
Dec 10
2020
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
3,000
-5.5%
|
$210,000
$70.8 P/Share
|
|
Dec 09
2020
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
38,676
-0.38%
|
$2,668,644
$69.89 P/Share
|
|
Dec 09
2020
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,676
+1.5%
|
$77,352
$2.01 P/Share
|
|
Dec 08
2020
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,324
-0.65%
|
$1,093,708
$67.97 P/Share
|
|
Dec 08
2020
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,324
+0.64%
|
$32,648
$2.01 P/Share
|
|
Dec 07
2020
|
Douglas B Given Director |
BUY
Bona fide gift
|
Indirect |
31,000
+50.0%
|
-
|
|
Dec 07
2020
|
Douglas B Given Director |
SELL
Bona fide gift
|
Direct |
31,000
-20.02%
|
-
|
|
Dec 04
2020
|
Patrick O'Brien COO and General Counsel |
SELL
Bona fide gift
|
Direct |
800
-0.23%
|
-
|
|
Nov 20
2020
|
Curt Bradshaw Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,625
-100.0%
|
$1,062,500
$68.73 P/Share
|
|
Nov 19
2020
|
Curt Bradshaw Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,625
-50.0%
|
$1,078,125
$69.39 P/Share
|
|
Nov 19
2020
|
Martin Javier San Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,500
-13.0%
|
$1,345,500
$69.39 P/Share
|
|
Nov 09
2020
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
43,505
-4.73%
|
$3,001,845
$69.45 P/Share
|
|
Nov 09
2020
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,505
+8.45%
|
$609,070
$14.54 P/Share
|
|
Oct 23
2020
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-1.93%
|
$5,800,000
$58.37 P/Share
|
|
Oct 20
2020
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
29,166
-6.38%
|
$1,574,964
$54.04 P/Share
|
|
Oct 20
2020
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,166
+6.0%
|
$174,996
$6.15 P/Share
|
|
Oct 09
2020
|
Mauro Ferrari Director |
SELL
Open market or private sale
|
Direct |
10,000
-24.41%
|
$480,000
$48.0 P/Share
|
|
Oct 08
2020
|
Marianne De Backer Director |
BUY
Open market or private purchase
|
Direct |
1,000
+2.82%
|
$50,000
$50.47 P/Share
|